ALK	Anaplastic lymphoma kinase
AMEA	Asia-Pacific and the Middle East
CA19-9	Carbohydrate antigen 19-9
CEA	Carcinoembryonic antigen
CI	Confidence interval
CRT	Chemoradiotherapy
CT	Computed tomography
ctDNA	Circulating tumor DNA
DFS	Disease-free survival
DMR	Differentially methylated regions
EBUS-TBNA	Endobronchial ultrasound-guided transbronchial needle aspiration
EBV	Epstein–Barr virus
EGFR	Epidermal growth factor receptor
HR	Hazard ratio
MRD	Molecular residual disease
MRI	Magnetic resonance imaging
NED	No evidence of disease
NGS	Next-generation sequencing
NSCLC	Non-small cell lung cancer
OS	Overall survival
PD-L1	Programmed death-ligand 1
PET	Positron emission tomography
PFS	Progression-free survival
RFS	Recurrence-free survival
RUL	Right upper lobe
SUV	Standardized uptake value
TAT	Turnaround time
TF	Methylation tumor fraction
TTF-1	Thyroid transcription factor 1
TPS	Tumor proportion score
VAF	Variant allele fraction
VATS	Video-assisted thoracoscopic surgery